MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

 

 

 


 

Back to products

 

 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

 


Other drug agents

Drug intermediates

Bio-reagents and biochemicals

 

 

 

 

 

 

 

 

MedKoo product information:

  

 CEP-28122

    

Description of CEP-28122:  CEP-28122 is a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. (source: Mol Cancer Ther; 11(3); 670-9.)

  

Current developer: Cephalon (now part of Teva Pharm).

   

MedKoo Code#:  401213

Name: CEP-28122

CAS#:  1022958-60-6 (CEP-28122 free base); 1354545-57-5 (CEP28122 mesylate salt)

 

Synonym:  CEP-28122

   

IUPAC/Chemical name: 

(1S,2S,3R,4R)-3-((5-chloro-2-(((S)-1-methoxy-7-morpholino-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)bicyclo[2.2.1]hept-5-ene-2-carboxamide

 

Chemical structure

Theoretical analysis

 

 

 

 

Chemical Formula: C28H35ClN6O3

Exact Mass: 538.24592

Molecular Weight: 539.06890

Elemental Analysis: C, 62.39; H, 6.54; Cl, 6.58; N, 15.59; O, 8.90

  

   

Availability and price:

 

This agent is  available through  custom synthesis.

   

To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

 

  

Information about this agent

 

In vitro activity of CEP-28122: the follow data was reported by Cheng M et al.

  

  (data reported in Mol Cancer Ther. 2012 Mar;11(3):670-9.)

 

References

1: Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Cristofani F, Machiorlatti R, Abele C, Ator MA, Dorsey BD, Inghirami G, Ruggeri BA. CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. Mol Cancer Ther. 2012 Mar;11(3):670-9. Epub 2011 Dec 27. PubMed PMID: 22203728.

 

 

 

Contact MedKoo:

Email: sales@medkoo.com

 

(Keyword; CAS#; MedKoo code#)

 

 

 

 

 

 

 

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

© MedKoo Biosciences. All Rights Reserved